Related Experiment Videos
[Transfusion-related acute lung injury]
1Dept. of Hematology, Hadassah-University Hospital, Ein Karem, Jerusalem.
Harefuah
|January 1, 1993
Summary
Transfusion-related acute lung injury (TRALI) causes respiratory distress post-transfusion. Prompt corticosteroid treatment led to rapid recovery in two patients, highlighting a favorable prognosis for this ARDS subtype.
Area of Science:
- Critical Care Medicine
- Transfusion Medicine
- Immunology
Background:
- Transfusion-related acute lung injury (TRALI) is a severe complication following blood product transfusion.
- TRALI presents with acute respiratory distress, fever, chills, and characteristic radiographic findings.
- The pathophysiology involves immune reactions, primarily due to antileukocyte antibodies in transfused products.
Observation:
- Two patients developed TRALI shortly after blood product transfusion.
- Clinical presentation included severe dyspnea, fever, chills, and bilateral lung crepitations.
- Diagnostic imaging revealed diffuse patchy infiltrates, and blood gas analysis indicated severe hypoxemia.
Findings:
- Both patients received high-dose corticosteroids (1 g methylprednisolone).
- Treatment resulted in complete recovery within 96 hours for both individuals.
- This suggests a significant therapeutic response to corticosteroids in TRALI.
Implications:
- Medical professionals should recognize TRALI as a distinct subtype of acute respiratory distress syndrome (ARDS).
- Early recognition and prompt administration of corticosteroids may lead to favorable outcomes.
- Awareness of this treatment-responsive ARDS variant is crucial for improving patient prognosis.